Statin therapy in chronic viral hepatitis: a systematic review and meta-analysis of nine studies with 195,602 participants

References

• 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;290:140–205.
   PubMed Web of Science ®Google Scholar
• Nikolic D, Banach M, Chianetta R, et al. An overview of statin-induced myopathy and perspectives for the future. Expert Opin Drug Saf. 2020;19(5):601–615.
   PubMed Web of Science ®Google Scholar
• Banach M, Rizzo M, Toth PP, et al. Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci. 2015;11(1):1–23.
   PubMed Web of Science ®Google Scholar
• Banach M, Stulc T, Dent R, et al. Statin non-adherence and residual cardiovascular risk: there is need for substantial improvement. Int J Cardiol. 2016;225:184–196.
   PubMed Web of Science ®Google Scholar
• Rosenson RS, Baker S, Banach M, et al. Optimizing cholesterol treatment in patients with muscle complaints. J Am Coll Cardiol. 2017;70(10):1290–1301.
   PubMed Web of Science ®Google Scholar
• Qu H, Meng YY, Chai H, et al. The effect of statin treatment on circulating coenzyme Q10 concentrations: an updated meta-analysis of randomized controlled trials. Eur J Med Res. 2018;23(1):57.
   PubMed Web of Science ®Google Scholar
• Banach M, Serban C, Ursoniu S, et al. Statin therapy and plasma coenzyme Q10 concentrations–a systematic review and meta-analysis of placebo-controlled trials. Pharmacol Res. 2015;99:329–336.
   PubMed Web of Science ®Google Scholar
• Sahebkar A, Cicero AFG, Di Giosia P, et al. Pathophysiological mechanisms of statin-associated myopathies: possible role of the ubiquitin-proteasome system. J Cachexia Sarcopenia Muscle. 2020;11(5):1177–1186.
   PubMed Web of Science ®Google Scholar
• Suthers G, Somogyi AA. Pharmacogenetics of statin intolerance. Intern Med J. 2020;50(4):506–507.
   PubMed Web of Science ®Google Scholar
• Licata A, Giammanco A, Minissale MG, et al. Liver and statins: a critical appraisal of the evidence. Curr Med Chem. 2018;25(42):5835–5846.
   PubMed Web of Science ®Google Scholar
• deLemos AS, Foureau DM, Jacobs C, et al. Drug-induced liver injury with autoimmune features. Semin Liver Dis. 2014;34(2):194–204.
   PubMed Web of Science ®Google Scholar
• Cicero AFG, Landolfo M, Ventura F, et al. Current pharmacotherapeutic options for primary dyslipidemia in adults. Expert Opin Pharmacother. 2019;20(10):1277–1288.
   PubMed Web of Science ®Google Scholar
• Khan AA, Ahmed S, Mohammed A, Elzouki AY. Autoimmune-like drug-induced liver injury caused by atorvastatin and demonstration of the safety profile of pravastatin: a case report and literature review. Cureus. 2020;12(3):e7299.
   PubMed Web of Science ®Google Scholar
• Shah J, Lingiah V, Pyrsopoulos N, et al. Acute liver injury in a patient treated with rosuvastatin: a rare adverse effect. Gastroenterol Res. 2019;12(5):263–266.
   PubMed Web of Science ®Google Scholar
• Guo M, Zhao J, Zhai Y, et al. A prospective study of hepatic safety of statins used in very elderly patients. BMC Geriatr. 2019;19(1):352.
   PubMed Web of Science ®Google Scholar
• Soran H, France M, Adam S, et al. Quantitative evaluation of statin effectiveness versus intolerance and strategies for management of intolerance. Atherosclerosis. 2020;306:33–40.
   PubMed Web of Science ®Google Scholar
• Milazzo L, Menzaghi B, Corvasce S, et al. Safety of statin therapy in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr. 2007;46(2):258–260.
   PubMed Web of Science ®Google Scholar
• Bosch J, Forns X. Therapy. Statins and liver disease: from concern to 'wonder' drugs? Nat Rev Gastroenterol Hepatol. 2015;12(6):320–321.
   PubMed Web of Science ®Google Scholar
• Imprialos KP, Stavropoulos K, Doumas M, et al. The potential role of statins in treating liver disease. Expert Rev Gastroenterol Hepatol. 2018;12(4):331–339.
   PubMed Web of Science ®Google Scholar
• Wang T, Wang F, Gou Z, et al. Using real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1,324,515 patients from observational studies. Diabetes Obes Metab. 2015;17(1):32–41.
   PubMed Web of Science ®Google Scholar
• Saragiotto BT, Yamato TP, Hespanhol Junior LC, et al. What are the main risk factors for running-related injuries? Sports Med. 2014;44(8):1153–1163.
   PubMed Web of Science ®Google Scholar
• Sardana V, Burzynski J, Zalzal P. Safety and efficacy of topical ketoprofen in transfersome gel in knee osteoarthritis: a systematic review. Musculoskeletal Care. 2017;15(2):114–121.
   PubMed Web of Science ®Google Scholar
• McGrath S, Zhao X, Steele R, et al. Estimating the sample mean and standard deviation from commonly reported quantiles in meta-analysis. Stat Methods Med Res. 2020;29(9):2520–2537.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
   PubMed Web of Science ®Google Scholar
• Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–634.
   PubMed Web of Science ®Google Scholar
• Viechtbauer W, Cheung MW. Outlier and influence diagnostics for meta-analysis. Res Synth Methods. 2010;1(2):112–125.
   PubMed Web of Science ®Google Scholar
• Baujat B, Mahé C, Pignon JP, et al. A graphical method for exploring heterogeneity in meta-analyses: application to a meta-analysis of 65 trials. Stat Med. 2002;21(18):2641–2652.
   PubMed Web of Science ®Google Scholar
• Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology. 2007;46(1):32–36.
   PubMed Web of Science ®Google Scholar
• Gu Y, Yang X, Liang H, et al. Comprehensive evaluation of effects and safety of statin on the progression of liver cirrhosis: a systematic review and meta-analysis. BMC Gastroenterol. 2019;19(1):231.
   PubMed Web of Science ®Google Scholar
• Ma X, Sun D, Li C, et al. Statin use and virus-related cirrhosis: a systemic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2017;41(5):533–542.
   PubMed Web of Science ®Google Scholar
• Kim RG, Loomba R, Prokop LJ, et al. Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2017;15(10):1521–1530. e8.
   PubMed Web of Science ®Google Scholar
• Zheng YX, Zhou PC, Zhou RR, et al. The benefit of statins in chronic hepatitis C patients: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2017;29(7):759–766.
   PubMed Web of Science ®Google Scholar
• Liang X, He Q, Zhao Q. Effect of stains on LDL reduction and liver safety: a systematic review and meta-analysis. Biomed Res Int. 2018;2018:7092414.
   PubMed Web of Science ®Google Scholar
• Mach F, Ray KK, Wiklund O, et al. Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. Eur Heart J. 2018;39(27):2526–2539.
   PubMed Web of Science ®Google Scholar
• Newman CB, Preiss D, Tobert JA, et al. Statin safety and associated adverse events: a scientific statement from the American Heart Association. ATVB. 2019;39(2):e38–e81.
   Google Scholar
• Afshari AR, Mollazadeh H, Henney NC, et al. Effects of statins on brain tumors: a review. Semin Cancer Biol. 2021;73:116–133.
   PubMed Web of Science ®Google Scholar
• Bagheri H, Ghasemi F, Barreto GE, et al. The effects of statins on microglial cells to protect against neurodegenerative disorders: a mechanistic review. Biofactors. 2020;46(3):309–325.
   PubMed Web of Science ®Google Scholar
• Bahrami A, Bo S, Jamialahmadi T, et al. Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on ageing: molecular mechanisms. Ageing Res Rev. 2020;58:101024.
   PubMed Web of Science ®Google Scholar
• Bianconi V, Sahebkar A, Banach M, et al. Statins, haemostatic factors and thrombotic risk. Curr Opin Cardiol. 2017;32(4):460–466.
   PubMed Web of Science ®Google Scholar
• Gorabi AM, Kiaie N, Pirro M, et al. Effects of statins on the biological features of mesenchymal stem cells and therapeutic implications. Heart Failure Rev. 2020. DOI:10.1007/s10741-020-09929-9
   PubMed Web of Science ®Google Scholar
• Kouhpeikar H, Delbari Z, Sathyapalan T, et al. The effect of statins through mast cells in the pathophysiology of atherosclerosis: a review. Curr Atheroscler Rep. 2020;22(5):19.
   PubMed Web of Science ®Google Scholar
• Koushki K, Shahbaz SK, Mashayekhi K, et al. Anti-inflammatory action of statins in cardiovascular disease: the role of inflammasome and toll-like receptor pathways. Clin Rev Allergy Immunol. 2021;60(2):175–199.
   PubMed Web of Science ®Google Scholar
• Sahebkar A, Serban C, Ursoniu S, et al. The impact of statin therapy on plasma levels of von Willebrand factor antigen: systematic review and meta-analysis of randomised placebo-controlled trials. Thromb Haemost. 2016;115(03):520–532.
   PubMedGoogle Scholar
• Serban C, Sahebkar A, Ursoniu S, et al. A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations. Sci Rep. 2015;5(1):9902.
   PubMedGoogle Scholar
• Costa S, Reina-Couto M, Albino-Teixeira A, et al. Statins and oxidative stress in chronic heart failure. Revista Portuguesa de Cardiologia: orgao Oficial da Sociedade Portuguesa de Cardiologia = Portuguese J Cardiol. 2016;35(1):41–57.
   PubMedGoogle Scholar
• Lee SH, Choi NY, Yu HJ, et al. Atorvastatin protects NSC-34 motor neurons against oxidative stress by activating PI3K, ERK and free radical scavenging. Mol Neurobiol. 2016;53(1):695–705.
   PubMed Web of Science ®Google Scholar
• Athyros VG, Alexandrides TK, Bilianou H, et al. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel statement. Metabolism. 2017;71:17–32.
   PubMed Web of Science ®Google Scholar
• Schierwagen R, Uschner FE, Magdaleno F, et al. Rationale for the use of statins in liver disease. Am J Physiol Gastrointest Liver Physiol. 2017;312(5):G407–g12.
   PubMed Web of Science ®Google Scholar
• Chen Z, Yu R, Xiong Y, et al. A vicious circle between insulin resistance and inflammation in nonalcoholic fatty liver disease. Lipids Health Dis. 2017;16(1):203.
   PubMedGoogle Scholar
• Zhao TY, Su LP, Ma CY, et al. IGF-1 decreases portal vein endotoxin via regulating intestinal tight junctions and plays a role in attenuating portal hypertension of cirrhotic rats. BMC Gastroenterol. 2015;15:77.
   PubMed Web of Science ®Google Scholar
• Fattovich G, Stroffolini T, Zagni I, et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127(5 Suppl 1):S35–S50.
   PubMed Web of Science ®Google Scholar
• Barbarash O, Gruzdeva O, Uchasova E, et al. Dose-dependent effects of atorvastatin on myocardial infarction. Drug Des Devel Ther. 2015;9:3361–3368.
   PubMed Web of Science ®Google Scholar
• Henein M, Granåsen G, Wiklund U, et al. High dose and long-term statin therapy accelerate coronary artery calcification. Int J Cardiol. 2015;184:581–586.
   PubMed Web of Science ®Google Scholar
• Facciorusso A, Abd El Aziz MA, Singh S, et al. Statin use decreases the incidence of hepatocellular carcinoma: an updated meta-analysis. Cancers. 2020;12(4):874.
   PubMed Web of Science ®Google Scholar
• Simon TG, Duberg AS, Aleman S, et al. Lipophilic statins and risk for hepatocellular carcinoma and death in patients with chronic viral hepatitis: results from a nationwide Swedish population. Ann Intern Med. 2019;171(5):318–327.
   PubMed Web of Science ®Google Scholar
• Tsan YT, Lee CH, Wang JD, et al. Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. J Clin Oncol. 2012;30(6):623–630.
   PubMed Web of Science ®Google Scholar